Molecular classification and construction of the risk signature for diffuse large B-cell lymphoma based on vitamin B6 metabolism
Abstract Background and objectives Diffuse large B-cell lymphoma (DLBCL), characterized by high heterogeneity, shows significant differences in treatment responses and prognosis among patients. The underlying mechanisms of vitamin B6 metabolism in DLBCL remain unclear. This study aims to explore vit...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-07-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-03122-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849332539104165888 |
|---|---|
| author | Wen Wei Dao Xin Huawei Weng Le Yu Lingxi Jiang Yuxin Man |
| author_facet | Wen Wei Dao Xin Huawei Weng Le Yu Lingxi Jiang Yuxin Man |
| author_sort | Wen Wei |
| collection | DOAJ |
| description | Abstract Background and objectives Diffuse large B-cell lymphoma (DLBCL), characterized by high heterogeneity, shows significant differences in treatment responses and prognosis among patients. The underlying mechanisms of vitamin B6 metabolism in DLBCL remain unclear. This study aims to explore vitamin B6 metabolism characteristics, identify novel DLBCL molecular subtypes, and establish a predictive signature for prognosis. Methods We first conducted Mendelian randomization (MR) analysis to investigate the genetic association between the vitamin B6 metabolism gene and lymphoma. Subsequently, we utilized weighted gene co-expression network analysis (WGCNA) to identify vitamin B6 metabolism-related genes in DLBCL, combined with non-negative matrix factorization (NMF) to distinguish different molecular subtypes. On this basis, we constructed a risk signature using univariate Cox regression, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression. External validation of the signature was performed. Finally, we integrated clinical features to establish a nomogram to predict survival probabilities precisely. Results The vitamin B6 metabolism gene PSAT1 may play a protective role in lymphoma. Based on vitamin B6 metabolism features, we successfully identified four distinct DLBCL molecular subtypes. The constructed risk signature effectively assessed patients’ risk status and combined clinical features to establish a nomogram. This signature can precisely predict 1-year, 3-year, and 5-year survival probabilities for DLBCL patients, providing essential references for individualized management. Conclusion This study identified novel DLBCL molecular subtypes based on vitamin B6 metabolism characteristics and established a risk signature with clinical application value. These findings provide a new direction for the precise management of DLBCL patients. |
| format | Article |
| id | doaj-art-829f2debd77d4af7ad4e237e765b2cfd |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-829f2debd77d4af7ad4e237e765b2cfd2025-08-20T03:46:09ZengSpringerDiscover Oncology2730-60112025-07-0116111810.1007/s12672-025-03122-wMolecular classification and construction of the risk signature for diffuse large B-cell lymphoma based on vitamin B6 metabolismWen Wei0Dao Xin1Huawei Weng2Le Yu3Lingxi Jiang4Yuxin Man5Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of ChinaDepartment of Oncology, The First Affiliated Hospital of Zhengzhou UniversityDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of ChinaDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of ChinaSichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, University of Electronic Science and TechnologyDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of ChinaAbstract Background and objectives Diffuse large B-cell lymphoma (DLBCL), characterized by high heterogeneity, shows significant differences in treatment responses and prognosis among patients. The underlying mechanisms of vitamin B6 metabolism in DLBCL remain unclear. This study aims to explore vitamin B6 metabolism characteristics, identify novel DLBCL molecular subtypes, and establish a predictive signature for prognosis. Methods We first conducted Mendelian randomization (MR) analysis to investigate the genetic association between the vitamin B6 metabolism gene and lymphoma. Subsequently, we utilized weighted gene co-expression network analysis (WGCNA) to identify vitamin B6 metabolism-related genes in DLBCL, combined with non-negative matrix factorization (NMF) to distinguish different molecular subtypes. On this basis, we constructed a risk signature using univariate Cox regression, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression. External validation of the signature was performed. Finally, we integrated clinical features to establish a nomogram to predict survival probabilities precisely. Results The vitamin B6 metabolism gene PSAT1 may play a protective role in lymphoma. Based on vitamin B6 metabolism features, we successfully identified four distinct DLBCL molecular subtypes. The constructed risk signature effectively assessed patients’ risk status and combined clinical features to establish a nomogram. This signature can precisely predict 1-year, 3-year, and 5-year survival probabilities for DLBCL patients, providing essential references for individualized management. Conclusion This study identified novel DLBCL molecular subtypes based on vitamin B6 metabolism characteristics and established a risk signature with clinical application value. These findings provide a new direction for the precise management of DLBCL patients.https://doi.org/10.1007/s12672-025-03122-wDiffuse large B-cell lymphomaVitamin B6 metabolismMolecular subtypePrognosisSignature |
| spellingShingle | Wen Wei Dao Xin Huawei Weng Le Yu Lingxi Jiang Yuxin Man Molecular classification and construction of the risk signature for diffuse large B-cell lymphoma based on vitamin B6 metabolism Discover Oncology Diffuse large B-cell lymphoma Vitamin B6 metabolism Molecular subtype Prognosis Signature |
| title | Molecular classification and construction of the risk signature for diffuse large B-cell lymphoma based on vitamin B6 metabolism |
| title_full | Molecular classification and construction of the risk signature for diffuse large B-cell lymphoma based on vitamin B6 metabolism |
| title_fullStr | Molecular classification and construction of the risk signature for diffuse large B-cell lymphoma based on vitamin B6 metabolism |
| title_full_unstemmed | Molecular classification and construction of the risk signature for diffuse large B-cell lymphoma based on vitamin B6 metabolism |
| title_short | Molecular classification and construction of the risk signature for diffuse large B-cell lymphoma based on vitamin B6 metabolism |
| title_sort | molecular classification and construction of the risk signature for diffuse large b cell lymphoma based on vitamin b6 metabolism |
| topic | Diffuse large B-cell lymphoma Vitamin B6 metabolism Molecular subtype Prognosis Signature |
| url | https://doi.org/10.1007/s12672-025-03122-w |
| work_keys_str_mv | AT wenwei molecularclassificationandconstructionoftherisksignaturefordiffuselargebcelllymphomabasedonvitaminb6metabolism AT daoxin molecularclassificationandconstructionoftherisksignaturefordiffuselargebcelllymphomabasedonvitaminb6metabolism AT huaweiweng molecularclassificationandconstructionoftherisksignaturefordiffuselargebcelllymphomabasedonvitaminb6metabolism AT leyu molecularclassificationandconstructionoftherisksignaturefordiffuselargebcelllymphomabasedonvitaminb6metabolism AT lingxijiang molecularclassificationandconstructionoftherisksignaturefordiffuselargebcelllymphomabasedonvitaminb6metabolism AT yuxinman molecularclassificationandconstructionoftherisksignaturefordiffuselargebcelllymphomabasedonvitaminb6metabolism |